Department of Urology, University of North Carolina, 2105 Physician's Office Building, 170 Manning Dr, CB 7235, Chapel Hill, NC 27599-7235. Email:
Am J Manag Care. 2021 Aug 1;27(8):e278-e286. doi: 10.37765/ajmc.2021.88729.
Health systems and provider groups currently lack a systematic mechanism to evaluate the financial implications of value-based alternative payments. We sought to develop a method to prospectively quantify the financial implications, including risk and uncertainty of (1) transitioning from a fee-for-service to an episode-based payment model and (2) modifying episode-specific clinical cost drivers. Finally, we highlight practical applications for the model to help facilitate stakeholder engagement in the transition to value-based payment models.
We created a financial simulation from empirical data to demonstrate the feasibility and potential use cases within the context of a hypothetical episode-based payment model for prostate cancer surgery (prostatectomy).
We used Monte Carlo simulation methods to predict financial outcomes under various clinical and payment model scenarios for our pilot prostatectomy episode use case. We input patient-level empirical cost, reimbursement, and clinical data for a cohort of 157 patients at our institution into our model to quantify expected financial outcomes (payments, financial margins) and financial risk for stakeholders (payer, hospital, providers) under an episode-based payment model.
Compared with the status quo, there is a range of expected financial outcomes for various stakeholders depending on the financial parameters (episode price, shared savings, downside risk, stop-loss) in an episode-based payment model. Modifying clinical cost drivers has a profound impact on these outcomes. Uncertainty is high due to the small number of episodes.
The simulation demonstrates that both financial parameters and clinical cost drivers significantly affect the expected financial outcomes for stakeholders in value-based payment models.
医疗体系和医疗机构目前缺乏系统的机制来评估基于价值的替代支付的财务影响。我们试图开发一种方法,前瞻性地量化(1)从按服务收费向基于病例的支付模式转变和(2)修改特定病例临床成本驱动因素的财务影响,包括风险和不确定性。最后,我们强调了该模型的实际应用,以帮助促进利益相关者参与向基于价值的支付模式的转变。
我们从经验数据中创建了一个财务模拟,以展示在前列腺癌手术(前列腺切除术)的假设基于病例的支付模型背景下的可行性和潜在用例。
我们使用蒙特卡罗模拟方法来预测我们的试点前列腺切除术病例使用案例的各种临床和支付模型场景下的财务结果。我们将我们机构的 157 名患者的患者水平经验成本、报销和临床数据输入到我们的模型中,以量化基于病例的支付模型下利益相关者(付款人、医院、提供者)的预期财务结果(付款、财务利润率)和财务风险。
与现状相比,基于病例的支付模型中的财务参数(病例价格、共享储蓄、下行风险、止损)会导致各种利益相关者的预期财务结果存在一定范围。修改临床成本驱动因素对这些结果有深远的影响。由于病例数量较少,不确定性很高。
该模拟表明,财务参数和临床成本驱动因素都会显著影响基于价值的支付模型中利益相关者的预期财务结果。